Galantamine
Galantamine
CLINICAL USE
Mild to moderate dementia in Alzheimer’s disease
DOSE IN NORMAL RENAL FUNCTION
4–12 mg twice daily
PHARMACOKINETICS
Molecular weight                           :368.3 (as hydrobromide) %Protein binding                           :18 %Excreted unchanged in urine     : 18–22 Volume of distribution (L/kg)       :175 litreshalf-life – normal/ESRD (hrs)      :7–8 (XL: 8–10)/Increased DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function but start with lower doses DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Dialysed. Dose as in GFR <10           : mL/min HD                     :Dialysed. Dose as in GFR <10           : mL/minHDF/high flux   :Dialysed. Dose as in GFR <10           : mL/minCAV/VVHD      :Dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntibacterials: erythromycin increases plasma concentration of galantamine ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
–
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home